[
  {
    "bcr_patient_uuid": "8ee720b5-6f3a-4921-85ab-70e75c0835b0",
    "patient_ID": "TCGA.A3.3317",
    "bcr_drug_barcode": "TCGA-A3-3317-D1484",
    "bcr_drug_uuid": "7e3935a4-8f96-406a-a319-7377608652fa",
    "form_completion_date": "2010-5-13",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 605,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 886,
    "drug_units": "MG",
    "drug_dose": 800,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "8ee720b5-6f3a-4921-85ab-70e75c0835b0",
    "patient_ID": "TCGA.A3.3317",
    "bcr_drug_barcode": "TCGA-A3-3317-D1485",
    "bcr_drug_uuid": "e64308cc-327e-4629-94e4-c6c056787f2b",
    "form_completion_date": "2010-5-13",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 605,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 886,
    "drug_units": "M[IU]",
    "drug_dose": 0.5,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "3372a7d2-79cb-4cf0-9a7e-fe1a6b205daa",
    "patient_ID": "TCGA.A3.3347",
    "bcr_drug_barcode": "TCGA-A3-3347-D4931",
    "bcr_drug_uuid": "c055dcd8-9968-40c8-9107-059cf2adea95",
    "form_completion_date": "2010-9-12",
    "pharmaceutical_therapy_drug_name": "PERIFOSINE",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1097,
    "pharmaceutical_tx_ongoing_indicator": false,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3372a7d2-79cb-4cf0-9a7e-fe1a6b205daa",
    "patient_ID": "TCGA.A3.3347",
    "bcr_drug_barcode": "TCGA-A3-3347-D4930",
    "bcr_drug_uuid": "2610bbd4-b2a1-4e02-bf42-3b575f94f763",
    "form_completion_date": "2010-9-12",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "c5265ca6-2cb5-406d-a635-c4c783561107",
    "patient_ID": "TCGA.AK.3426",
    "bcr_drug_barcode": "TCGA-AK-3426-D4313",
    "bcr_drug_uuid": "3ebcad24-5a0f-4565-9401-f3ebf8fefad7",
    "form_completion_date": "2010-11-10",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 465,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 522,
    "drug_dose": 3,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "b2feca3f-8602-4a30-92bf-958ab2a2bd5d",
    "patient_ID": "TCGA.AK.3436",
    "bcr_drug_barcode": "TCGA-AK-3436-D4346",
    "bcr_drug_uuid": "200c01cf-2051-46d4-a755-4b291b488e77",
    "form_completion_date": "2010-11-12",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 76,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_dose": 37.5,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "b2feca3f-8602-4a30-92bf-958ab2a2bd5d",
    "patient_ID": "TCGA.AK.3436",
    "bcr_drug_barcode": "TCGA-AK-3436-D66269",
    "bcr_drug_uuid": "E1720391-E83A-499D-8AA3-FBDFC1EB92D3",
    "form_completion_date": "2014-10-7",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1194,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "fd5728e0-e495-45f5-aac8-c0856510c8aa",
    "patient_ID": "TCGA.AK.3453",
    "bcr_drug_barcode": "TCGA-AK-3453-D4355",
    "bcr_drug_uuid": "c4d89674-4155-4d65-8c93-6a0a92e587be",
    "form_completion_date": "2010-11-12",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "regimen_number": 1,
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "75801b19-6569-4345-8134-82344a412c21",
    "patient_ID": "TCGA.B0.4718",
    "bcr_drug_barcode": "TCGA-B0-4718-D71492",
    "bcr_drug_uuid": "CD80DE57-91F5-4915-970A-63855FA51F49",
    "form_completion_date": "2015-3-26",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 99,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1231,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "75801b19-6569-4345-8134-82344a412c21",
    "patient_ID": "TCGA.B0.4718",
    "bcr_drug_barcode": "TCGA-B0-4718-D71493",
    "bcr_drug_uuid": "2FDAAE91-FC6E-47C8-B600-0C2719CD0119",
    "form_completion_date": "2015-3-26",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1363,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1685,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "31e9d2fc-79fa-49db-adac-7afb9609f915",
    "patient_ID": "TCGA.B0.4837",
    "bcr_drug_barcode": "TCGA-B0-4837-D31227",
    "bcr_drug_uuid": "f44ccd53-1fa1-47aa-9344-0a6c8dff1cf2",
    "form_completion_date": "2012-4-25",
    "pharmaceutical_therapy_drug_name": "TYROSINE KINASE INHIBITOR",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1217,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "77d8c2cf-6b27-417b-9d43-14c95e6f9b85",
    "patient_ID": "TCGA.B0.4841",
    "bcr_drug_barcode": "TCGA-B0-4841-D31237",
    "bcr_drug_uuid": "af206997-7393-4f9e-a9d0-6dee745c7585",
    "form_completion_date": "2012-4-25",
    "pharmaceutical_therapy_drug_name": "INF",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 108,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4ee14e95-09d8-4512-b358-3e0e7cb74c9a",
    "patient_ID": "TCGA.B0.4844",
    "bcr_drug_barcode": "TCGA-B0-4844-D30999",
    "bcr_drug_uuid": "e5d040d0-8f40-42dc-afa0-a5318868d569",
    "form_completion_date": "2012-4-20",
    "pharmaceutical_therapy_drug_name": "IL-2",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4ee14e95-09d8-4512-b358-3e0e7cb74c9a",
    "patient_ID": "TCGA.B0.4844",
    "bcr_drug_barcode": "TCGA-B0-4844-D31001",
    "bcr_drug_uuid": "c3a07cf7-d164-4b2a-8fdb-c8dde5243f59",
    "form_completion_date": "2012-4-20",
    "pharmaceutical_therapy_drug_name": "THALIDOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 60,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8aaa4e25-5c12-4ace-96dc-91aaa0c4457c",
    "patient_ID": "TCGA.B0.5094",
    "bcr_drug_barcode": "TCGA-B0-5094-D31511",
    "bcr_drug_uuid": "e973d23d-8bec-4f9b-99c0-e10fbb0d6468",
    "form_completion_date": "2012-5-4",
    "pharmaceutical_therapy_drug_name": "TORISEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 124,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6b1ff32f-75a4-44aa-9da4-b6872e179c9f",
    "patient_ID": "TCGA.B0.5107",
    "bcr_drug_barcode": "TCGA-B0-5107-D31607",
    "bcr_drug_uuid": "1e2025bb-698c-4a31-9302-fe90f67db312",
    "form_completion_date": "2012-5-7",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 11,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "46bc69a9-0090-4809-92b8-8cb741d9007d",
    "patient_ID": "TCGA.B0.5115",
    "bcr_drug_barcode": "TCGA-B0-5115-D31669",
    "bcr_drug_uuid": "4394ed12-bf7a-429b-99c5-191808378871",
    "form_completion_date": "2012-5-8",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 197,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 197,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "46bc69a9-0090-4809-92b8-8cb741d9007d",
    "patient_ID": "TCGA.B0.5115",
    "bcr_drug_barcode": "TCGA-B0-5115-D31670",
    "bcr_drug_uuid": "cbb89ea4-88a3-4965-8468-5462ed62b9fe",
    "form_completion_date": "2012-5-8",
    "pharmaceutical_therapy_drug_name": "AFINITOR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 501,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "11111b58-c7df-4291-ad8a-4baec9ff7d1f",
    "patient_ID": "TCGA.B0.5694",
    "bcr_drug_barcode": "TCGA-B0-5694-D31875",
    "bcr_drug_uuid": "4ac87a38-e1a6-4778-8a93-48f6dc837641",
    "form_completion_date": "2012-5-10",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 441,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 469,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8f8a632d-7fbd-4c86-b909-afb7edb9ad28",
    "patient_ID": "TCGA.B0.5701",
    "bcr_drug_barcode": "TCGA-B0-5701-D72539",
    "bcr_drug_uuid": "5ED37448-8F4C-4B40-BA79-879C0E7025EC",
    "form_completion_date": "2015-7-13",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 366,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 727,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "514af471-31d2-43fa-88dc-8639a5e97181",
    "patient_ID": "TCGA.B0.5712",
    "bcr_drug_barcode": "TCGA-B0-5712-D31971",
    "bcr_drug_uuid": "fcf69248-81ae-4ab6-a197-b2b486da9e71",
    "form_completion_date": "2012-5-14",
    "pharmaceutical_therapy_drug_name": "ZOMETA",
    "days_to_drug_start": 177,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "73cb1350-7590-4f79-bb86-3f395466652e",
    "patient_ID": "TCGA.B2.5639",
    "bcr_drug_barcode": "TCGA-B2-5639-D15087",
    "bcr_drug_uuid": "a9334672-bbcb-4c0e-bc83-8e6e7dfdaedf",
    "form_completion_date": "2011-8-11",
    "pharmaceutical_therapy_drug_name": "TORISEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 158,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 275
  },
  {
    "bcr_patient_uuid": "73cb1350-7590-4f79-bb86-3f395466652e",
    "patient_ID": "TCGA.B2.5639",
    "bcr_drug_barcode": "TCGA-B2-5639-D15321",
    "bcr_drug_uuid": "036f3dd6-adad-435e-a474-903e289d323f",
    "form_completion_date": "2011-8-17",
    "pharmaceutical_therapy_drug_name": "VOTRIENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 177,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 241,
    "drug_units": "MG",
    "drug_dose": 200,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "dfa9513d-4e09-405b-a80f-2987ec5c5263",
    "patient_ID": "TCGA.B8.4143",
    "bcr_drug_barcode": "TCGA-B8-4143-D3365",
    "bcr_drug_uuid": "a34a2429-50ce-49f6-af1a-62f0687ea43e",
    "form_completion_date": "2010-11-16",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 388,
    "drug_cycles": 3,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTATIC DISEASE AT DIAGNOSIS"
  },
  {
    "bcr_patient_uuid": "a22d5ba2-5f11-49e9-911a-ec03b785fae5",
    "patient_ID": "TCGA.B8.4153",
    "bcr_drug_barcode": "TCGA-B8-4153-D12424",
    "bcr_drug_uuid": "39f4d6f0-b29e-47cf-b96c-70750f2ab203",
    "form_completion_date": "2011-6-1",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 238,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 1,
    "drug_units": "MG/DAY",
    "drug_dose": 800,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "d62d39f9-c896-4758-a785-e236f0154f14",
    "patient_ID": "TCGA.B8.5162",
    "bcr_drug_barcode": "TCGA-B8-5162-D17689",
    "bcr_drug_uuid": "bce01735-34e1-4c81-bb08-874717ffcb86",
    "form_completion_date": "2011-10-24",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": -58,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": -28,
    "drug_cycles": 1,
    "drug_units": "MG/DAY",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEOADJUVANT"
  },
  {
    "bcr_patient_uuid": "d9f1bb02-4cb0-4f7c-8f34-ff5f301c6b2c",
    "patient_ID": "TCGA.BP.4161",
    "bcr_drug_barcode": "TCGA-BP-4161-D9811",
    "bcr_drug_uuid": "48e716eb-d25e-434b-b899-55440e1e28b6",
    "form_completion_date": "2011-3-31",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2752,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3c1b6de7-c45f-4d86-be4b-a72ca7ca7cf9",
    "patient_ID": "TCGA.BP.4165",
    "bcr_drug_barcode": "TCGA-BP-4165-D10780",
    "bcr_drug_uuid": "9ef73876-67af-469e-90f8-430d1e6ff672",
    "form_completion_date": "2011-4-26",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2594,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 19,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3f05a719-e81e-4f0c-a5c1-f1733b7aba11",
    "patient_ID": "TCGA.BP.4169",
    "bcr_drug_barcode": "TCGA-BP-4169-D10867",
    "bcr_drug_uuid": "bf4d4656-1142-462e-b4e5-aeb06fe70832",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "AXITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 127,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 253,
    "drug_cycles": 6,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3f05a719-e81e-4f0c-a5c1-f1733b7aba11",
    "patient_ID": "TCGA.BP.4169",
    "bcr_drug_barcode": "TCGA-BP-4169-D10866",
    "bcr_drug_uuid": "eaa5273c-1fee-4fa9-9065-80dff2764426",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 36,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 78,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "6ccabcd0-8f30-4828-851f-0ac7cee1a33f",
    "patient_ID": "TCGA.BP.4329",
    "bcr_drug_barcode": "TCGA-BP-4329-D10883",
    "bcr_drug_uuid": "45ddd952-faa4-459a-8e61-5ee2fbd2a071",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 190,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 510,
    "drug_dose": 9000000,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "6ccabcd0-8f30-4828-851f-0ac7cee1a33f",
    "patient_ID": "TCGA.BP.4329",
    "bcr_drug_barcode": "TCGA-BP-4329-D10884",
    "bcr_drug_uuid": "9bf6d9f2-4e1f-450d-938a-99f2ca551f6d",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 204,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 510,
    "drug_units": "MG",
    "drug_dose": 15,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "e5eca191-f585-490d-81e3-9cced1047093",
    "patient_ID": "TCGA.BP.4334",
    "bcr_drug_barcode": "TCGA-BP-4334-D10945",
    "bcr_drug_uuid": "f1c101cf-ebc1-4e9f-b1d7-9e232a6703e1",
    "form_completion_date": "2011-5-2",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 520,
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_dose": 6000000,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "ed97aeee-2a5b-4361-ab4f-f53c3fc5f532",
    "patient_ID": "TCGA.BP.4335",
    "bcr_drug_barcode": "TCGA-BP-4335-D10965",
    "bcr_drug_uuid": "bb6c5138-3ac8-4e82-954f-554ed8e41733",
    "form_completion_date": "2011-5-2",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 134,
    "drug_cycles": 4,
    "drug_units": "MG/KG",
    "drug_dose": 4.5,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "4978eb8d-4a38-470b-9a00-6dd3aada1aa9",
    "patient_ID": "TCGA.BP.4338",
    "bcr_drug_barcode": "TCGA-BP-4338-D11006",
    "bcr_drug_uuid": "7b83d49a-3f0b-40ec-a14a-4e0f51023c24",
    "form_completion_date": "2011-5-2",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1765,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2450,
    "drug_cycles": 17,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "4978eb8d-4a38-470b-9a00-6dd3aada1aa9",
    "patient_ID": "TCGA.BP.4338",
    "bcr_drug_barcode": "TCGA-BP-4338-D11015",
    "bcr_drug_uuid": "187ebffd-f320-4e65-9abe-4622eb4d4edf",
    "form_completion_date": "2011-5-2",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2460,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2572,
    "drug_cycles": 4,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "4978eb8d-4a38-470b-9a00-6dd3aada1aa9",
    "patient_ID": "TCGA.BP.4338",
    "bcr_drug_barcode": "TCGA-BP-4338-D11017",
    "bcr_drug_uuid": "cb7f3030-e7de-4294-a627-6f083cd7db48",
    "form_completion_date": "2011-5-2",
    "pharmaceutical_therapy_drug_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2586,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_dose": 10,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "037c691e-6320-451b-9276-78459f1b705c",
    "patient_ID": "TCGA.BP.4352",
    "bcr_drug_barcode": "TCGA-BP-4352-D11087",
    "bcr_drug_uuid": "00ba7bc0-941c-421e-b252-a4520dfff776",
    "form_completion_date": "2011-5-3",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 35,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 59,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PALLIATIVE"
  },
  {
    "bcr_patient_uuid": "d9208e7b-0b47-43ff-a4e8-d4e591e286c4",
    "patient_ID": "TCGA.BP.4354",
    "bcr_drug_barcode": "TCGA-BP-4354-D9699",
    "bcr_drug_uuid": "6c38b574-14e5-4695-abe8-f6cb849dbbbf",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 10,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 454,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEOADJUVANT"
  },
  {
    "bcr_patient_uuid": "d9208e7b-0b47-43ff-a4e8-d4e591e286c4",
    "patient_ID": "TCGA.BP.4354",
    "bcr_drug_barcode": "TCGA-BP-4354-D9703",
    "bcr_drug_uuid": "bba9708b-8ae0-4cf6-b829-34d791507114",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 595,
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_units": "MG",
    "drug_dose": 200,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "d9208e7b-0b47-43ff-a4e8-d4e591e286c4",
    "patient_ID": "TCGA.BP.4354",
    "bcr_drug_barcode": "TCGA-BP-4354-D9704",
    "bcr_drug_uuid": "f671bce4-3fdd-4ead-a4d1-9c18c9202c37",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 721,
    "pharmaceutical_tx_ongoing_indicator": true,
    "regimen_number": 5,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "PATIENT CANNOT TOLERATE SORAFENIB"
  },
  {
    "bcr_patient_uuid": "d9208e7b-0b47-43ff-a4e8-d4e591e286c4",
    "patient_ID": "TCGA.BP.4354",
    "bcr_drug_barcode": "TCGA-BP-4354-D9701",
    "bcr_drug_uuid": "3672a244-cace-4004-87c5-a99ea6db94db",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 583,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 589,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "d9208e7b-0b47-43ff-a4e8-d4e591e286c4",
    "patient_ID": "TCGA.BP.4354",
    "bcr_drug_barcode": "TCGA-BP-4354-D9700",
    "bcr_drug_uuid": "f7b86ebd-d7e6-48f7-9409-d19f3255f60e",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 490,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 525,
    "drug_cycles": 3,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "d9208e7b-0b47-43ff-a4e8-d4e591e286c4",
    "patient_ID": "TCGA.BP.4354",
    "bcr_drug_barcode": "TCGA-BP-4354-D9749",
    "bcr_drug_uuid": "6c5d6738-1a45-445e-93cb-7724d8401079",
    "form_completion_date": "2011-3-31",
    "pharmaceutical_therapy_drug_name": "GEFITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 10,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 454,
    "drug_cycles": 11,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEOADJUVANT"
  },
  {
    "bcr_patient_uuid": "c3cc716b-1b9c-4e73-9a40-f1f891a17c2d",
    "patient_ID": "TCGA.BP.4770",
    "bcr_drug_barcode": "TCGA-BP-4770-D11188",
    "bcr_drug_uuid": "52c3f62f-beeb-4f58-b4e1-a829236a5240",
    "form_completion_date": "2011-5-4",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 211,
    "pharmaceutical_tx_ongoing_indicator": false,
    "drug_dose": 5000000,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "500636a5-d42b-469f-98e2-fdd4dddc61a0",
    "patient_ID": "TCGA.BP.4787",
    "bcr_drug_barcode": "TCGA-BP-4787-D11359",
    "bcr_drug_uuid": "6cde261d-db81-44f3-885d-a1202bb65401",
    "form_completion_date": "2011-5-9",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 333,
    "drug_cycles": 7,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METASTASIS"
  },
  {
    "bcr_patient_uuid": "500636a5-d42b-469f-98e2-fdd4dddc61a0",
    "patient_ID": "TCGA.BP.4787",
    "bcr_drug_barcode": "TCGA-BP-4787-D11361",
    "bcr_drug_uuid": "0fdec60b-14c1-443d-a7c6-b4f0f34159d0",
    "form_completion_date": "2011-5-9",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 361,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 388,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 400,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "500636a5-d42b-469f-98e2-fdd4dddc61a0",
    "patient_ID": "TCGA.BP.4787",
    "bcr_drug_barcode": "TCGA-BP-4787-D11362",
    "bcr_drug_uuid": "4edfe557-3699-45c5-8a0f-a1c831dbc79a",
    "form_completion_date": "2011-5-9",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 412,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 440,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "b81998f2-b3ff-4976-bc1c-8d38a68efa1d",
    "patient_ID": "TCGA.BP.4804",
    "bcr_drug_barcode": "TCGA-BP-4804-D21225",
    "bcr_drug_uuid": "fd535393-6afe-4ffb-bfd6-cb135562af1b",
    "form_completion_date": "2012-2-7",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1373,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_dose": 37.5,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "DOSE REDUCTION"
  },
  {
    "bcr_patient_uuid": "b81998f2-b3ff-4976-bc1c-8d38a68efa1d",
    "patient_ID": "TCGA.BP.4804",
    "bcr_drug_barcode": "TCGA-BP-4804-D21224",
    "bcr_drug_uuid": "fa5ad7b2-aefb-4f88-b687-342abbb3c338",
    "form_completion_date": "2012-2-7",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1289,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1359,
    "drug_cycles": 2,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "d6625c4d-cd1c-4c62-8100-e8b2a49ce3ad",
    "patient_ID": "TCGA.BP.4974",
    "bcr_drug_barcode": "TCGA-BP-4974-D9814",
    "bcr_drug_uuid": "0c9ca688-dbc5-4768-a966-40b9c23f8d80",
    "form_completion_date": "2011-3-31",
    "pharmaceutical_therapy_drug_name": "GEFITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 59,
    "drug_cycles": 1,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "d6625c4d-cd1c-4c62-8100-e8b2a49ce3ad",
    "patient_ID": "TCGA.BP.4974",
    "bcr_drug_barcode": "TCGA-BP-4974-D9813",
    "bcr_drug_uuid": "0ed85dba-57c4-4f24-b5c3-33cae30dc8de",
    "form_completion_date": "2011-3-31",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 58,
    "drug_cycles": 1,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "d6625c4d-cd1c-4c62-8100-e8b2a49ce3ad",
    "patient_ID": "TCGA.BP.4974",
    "bcr_drug_barcode": "TCGA-BP-4974-D9815",
    "bcr_drug_uuid": "7439b55d-69e9-4010-bcb3-b051ac46c94d",
    "form_completion_date": "2011-3-31",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 75,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 155,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "RE-STARTED TREATMENT"
  },
  {
    "bcr_patient_uuid": "d6625c4d-cd1c-4c62-8100-e8b2a49ce3ad",
    "patient_ID": "TCGA.BP.4974",
    "bcr_drug_barcode": "TCGA-BP-4974-D9816",
    "bcr_drug_uuid": "deb54796-0c89-40a5-a469-0ba39580ca2e",
    "form_completion_date": "2011-3-31",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 178,
    "pharmaceutical_tx_ongoing_indicator": false,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "c285ada3-fd49-46a5-882f-b6c352572e2a",
    "patient_ID": "TCGA.BP.4985",
    "bcr_drug_barcode": "TCGA-BP-4985-D11103",
    "bcr_drug_uuid": "45bfa7b8-f1d7-46e6-ab48-70cfc7b66d4f",
    "form_completion_date": "2011-5-2",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 307,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 728,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "57070e5b-0eb5-44b7-abb3-3007fa34543a",
    "patient_ID": "TCGA.BP.5009",
    "bcr_drug_barcode": "TCGA-BP-5009-D9678",
    "bcr_drug_uuid": "6e619ac0-1fae-4043-8203-45902fb4ce6f",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 338,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 577,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_dose": 50,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "RECURRENT AND METASTATIC"
  },
  {
    "bcr_patient_uuid": "57070e5b-0eb5-44b7-abb3-3007fa34543a",
    "patient_ID": "TCGA.BP.5009",
    "bcr_drug_barcode": "TCGA-BP-5009-D9680",
    "bcr_drug_uuid": "62753c86-2bba-4018-ba2b-f1bde4e757c3",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 609,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1023,
    "drug_cycles": 5,
    "drug_units": "MG",
    "drug_dose": 10,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "57070e5b-0eb5-44b7-abb3-3007fa34543a",
    "patient_ID": "TCGA.BP.5009",
    "bcr_drug_barcode": "TCGA-BP-5009-D9683",
    "bcr_drug_uuid": "acadf3e7-76af-4657-bcb0-f8ff07e5d8c2",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1029,
    "pharmaceutical_tx_ongoing_indicator": false,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "57070e5b-0eb5-44b7-abb3-3007fa34543a",
    "patient_ID": "TCGA.BP.5009",
    "bcr_drug_barcode": "TCGA-BP-5009-D9681",
    "bcr_drug_uuid": "418f9d32-3c0b-417a-a008-81977b4be13d",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 765,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 765,
    "drug_cycles": 1,
    "drug_units": "MG",
    "drug_dose": 800,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "6e9e5e05-2bf8-4724-8e31-241f517289de",
    "patient_ID": "TCGA.BP.5178",
    "bcr_drug_barcode": "TCGA-BP-5178-D9760",
    "bcr_drug_uuid": "6165a14b-241a-45c4-bbe9-6e5191d3e232",
    "form_completion_date": "2011-3-31",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 407,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 772,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "23c7555b-7a37-415d-bda8-3588078a0c2e",
    "patient_ID": "TCGA.BP.5189",
    "bcr_drug_barcode": "TCGA-BP-5189-D9666",
    "bcr_drug_uuid": "9540f223-bc67-458e-8ae1-e8de7f543e1c",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 661,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 773,
    "drug_units": "MG",
    "drug_dose": 25,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "23c7555b-7a37-415d-bda8-3588078a0c2e",
    "patient_ID": "TCGA.BP.5189",
    "bcr_drug_barcode": "TCGA-BP-5189-D9667",
    "bcr_drug_uuid": "effb694d-5c1a-44b8-a266-0d03ce5354f4",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 794,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 794,
    "drug_cycles": 1,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "54c9850c-9b67-42ea-a04b-16a88f786dfa",
    "patient_ID": "TCGA.BP.5201",
    "bcr_drug_barcode": "TCGA-BP-5201-D9676",
    "bcr_drug_uuid": "51a5697f-1fa8-410c-9d4b-f7596084fd9f",
    "form_completion_date": "2011-3-30",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 469,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 603,
    "drug_cycles": 2,
    "regimen_number": 1,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D6633",
    "bcr_drug_uuid": "a2b45ec6-a9e8-4e6e-b316-cd86e3db9123",
    "form_completion_date": "2011-1-24",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 476,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9507",
    "bcr_drug_uuid": "7d759b39-3ca8-4087-84f1-45f030189eac",
    "form_completion_date": "2011-3-24",
    "pharmaceutical_therapy_drug_name": "BORTEZOMIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1476,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1742,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9506",
    "bcr_drug_uuid": "e72b6d1a-b943-4cd7-9915-382face7ca16",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1962,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2053,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9501",
    "bcr_drug_uuid": "94cf2cda-aca4-49a9-b311-bfa9cf70196a",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 512,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 816,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9504",
    "bcr_drug_uuid": "54419681-f557-4d4d-8a03-a2dc7482a7d0",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1868,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1883,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9503",
    "bcr_drug_uuid": "43b4785b-3f0f-4184-be86-dacff571cf29",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "NAB-RAPAMYCIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1213,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1468,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9499",
    "bcr_drug_uuid": "191125ca-4520-483c-b644-25d9065e0a1c",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "ROFERON-A",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 476,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9500",
    "bcr_drug_uuid": "afce5403-0ffb-4b19-82a9-c8132d2d406a",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "INTRON A",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 484,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 507,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9502",
    "bcr_drug_uuid": "6fe89f3d-273f-4de3-9f20-bd7ed30440a4",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 849,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 861,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "772e3aed-f211-42a1-9ab2-1c543f581541",
    "patient_ID": "TCGA.CJ.4637",
    "bcr_drug_barcode": "TCGA-CJ-4637-D9505",
    "bcr_drug_uuid": "1ec9011a-b889-47c0-a845-6af51b872a8f",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "AZD",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1868,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1888,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "06197e26-3cb0-4bd0-a6e8-dd9af5047c6a",
    "patient_ID": "TCGA.CJ.4638",
    "bcr_drug_barcode": "TCGA-CJ-4638-D6635",
    "bcr_drug_uuid": "a35ff921-80b8-4e3f-8530-b47b5a68224c",
    "form_completion_date": "2011-1-24",
    "pharmaceutical_therapy_drug_name": "GEMICTIABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 160,
    "drug_cycles": 5,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "06197e26-3cb0-4bd0-a6e8-dd9af5047c6a",
    "patient_ID": "TCGA.CJ.4638",
    "bcr_drug_barcode": "TCGA-CJ-4638-D9421",
    "bcr_drug_uuid": "331065f1-e997-4f48-b80d-594232107917",
    "form_completion_date": "2011-3-23",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 252,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 281,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "06197e26-3cb0-4bd0-a6e8-dd9af5047c6a",
    "patient_ID": "TCGA.CJ.4638",
    "bcr_drug_barcode": "TCGA-CJ-4638-D9419",
    "bcr_drug_uuid": "0f9a0801-21be-4181-af14-88aeee0f9eaa",
    "form_completion_date": "2011-3-23",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 252,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "06197e26-3cb0-4bd0-a6e8-dd9af5047c6a",
    "patient_ID": "TCGA.CJ.4638",
    "bcr_drug_barcode": "TCGA-CJ-4638-D9420",
    "bcr_drug_uuid": "9bc6a537-f896-4571-b090-aa5369b2fdc7",
    "form_completion_date": "2011-3-23",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN-2",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 192,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 221,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "cdfa3c5d-2fe8-4dfd-92c2-a54f39f55f18",
    "patient_ID": "TCGA.CJ.4641",
    "bcr_drug_barcode": "TCGA-CJ-4641-D6637",
    "bcr_drug_uuid": "e62a1180-3ebc-4f8b-83bb-351a04aaef97",
    "form_completion_date": "2011-1-24",
    "pharmaceutical_therapy_drug_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 37,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 321,
    "drug_cycles": 9,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "8fd493c5-1375-4f76-b337-c9a75e3abdbe",
    "patient_ID": "TCGA.CJ.4644",
    "bcr_drug_barcode": "TCGA-CJ-4644-D9532",
    "bcr_drug_uuid": "b746fd6f-9a10-4c50-936e-541564bcd151",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "TARCEVA",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 229,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 316,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "8fd493c5-1375-4f76-b337-c9a75e3abdbe",
    "patient_ID": "TCGA.CJ.4644",
    "bcr_drug_barcode": "TCGA-CJ-4644-D9530",
    "bcr_drug_uuid": "7171cb82-3852-4fe2-bac7-14c6a3ab38aa",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 229,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 316,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "8fd493c5-1375-4f76-b337-c9a75e3abdbe",
    "patient_ID": "TCGA.CJ.4644",
    "bcr_drug_barcode": "TCGA-CJ-4644-D9529",
    "bcr_drug_uuid": "7d5cbe9b-e974-4f19-8878-6a0ba7996e82",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 229,
    "pharma_type_other": "VACCINE",
    "regimen_number": 1,
    "drug_route": "INTRAMUSCULAR",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "8fd493c5-1375-4f76-b337-c9a75e3abdbe",
    "patient_ID": "TCGA.CJ.4644",
    "bcr_drug_barcode": "TCGA-CJ-4644-D10750",
    "bcr_drug_uuid": "c9a68985-cd93-423c-87f0-5c0871107e5d",
    "form_completion_date": "2011-4-25",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 150,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 222,
    "drug_units": "G/DAY",
    "drug_dose": 2.5,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "8fd493c5-1375-4f76-b337-c9a75e3abdbe",
    "patient_ID": "TCGA.CJ.4644",
    "bcr_drug_barcode": "TCGA-CJ-4644-D10749",
    "bcr_drug_uuid": "48df2010-d4bd-4b71-af35-008ff98b2aea",
    "form_completion_date": "2011-4-25",
    "pharmaceutical_therapy_drug_name": "INTRON A",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 162,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 222,
    "drug_cycles": 1,
    "regimen_number": 2,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2309c424-26fa-4cc6-a22a-2dc0f989af59",
    "patient_ID": "TCGA.CJ.4868",
    "bcr_drug_barcode": "TCGA-CJ-4868-D6854",
    "bcr_drug_uuid": "42b8804d-3c4c-465e-af76-6758e70bad3c",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "PROLEUKIN",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 89,
    "drug_cycles": 2,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2309c424-26fa-4cc6-a22a-2dc0f989af59",
    "patient_ID": "TCGA.CJ.4868",
    "bcr_drug_barcode": "TCGA-CJ-4868-D9079",
    "bcr_drug_uuid": "0391be00-8514-4e2b-b975-bc795d2fcf45",
    "form_completion_date": "2011-3-13",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 296,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 365,
    "drug_cycles": 3,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2309c424-26fa-4cc6-a22a-2dc0f989af59",
    "patient_ID": "TCGA.CJ.4868",
    "bcr_drug_barcode": "TCGA-CJ-4868-D9080",
    "bcr_drug_uuid": "ee8e56ec-9936-46f8-aeb1-a67088026892",
    "form_completion_date": "2011-3-13",
    "pharmaceutical_therapy_drug_name": "NEXAVAR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 379,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 534,
    "drug_cycles": 1,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2309c424-26fa-4cc6-a22a-2dc0f989af59",
    "patient_ID": "TCGA.CJ.4868",
    "bcr_drug_barcode": "TCGA-CJ-4868-D9078",
    "bcr_drug_uuid": "47b7c613-8b63-4efc-8097-7f759a60240d",
    "form_completion_date": "2011-3-13",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 135,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 282,
    "drug_cycles": 10,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2309c424-26fa-4cc6-a22a-2dc0f989af59",
    "patient_ID": "TCGA.CJ.4868",
    "bcr_drug_barcode": "TCGA-CJ-4868-D9513",
    "bcr_drug_uuid": "11d4be47-87a8-4f0e-9466-a404b93acfb7",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "CAPECITABIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 296,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 365,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2309c424-26fa-4cc6-a22a-2dc0f989af59",
    "patient_ID": "TCGA.CJ.4868",
    "bcr_drug_barcode": "TCGA-CJ-4868-D9517",
    "bcr_drug_uuid": "8ed04635-5953-4258-85d0-a984c7a3ac4c",
    "form_completion_date": "2011-3-25",
    "pharmaceutical_therapy_drug_name": "TARCEVA",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 114,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 288,
    "drug_cycles": 10,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "06d86d68-0fd5-4c6e-8783-ed732a3291e8",
    "patient_ID": "TCGA.CJ.4869",
    "bcr_drug_barcode": "TCGA-CJ-4869-D7278",
    "bcr_drug_uuid": "5b6b47ff-9927-47ce-9709-808915090758",
    "form_completion_date": "2011-2-8",
    "pharmaceutical_therapy_drug_name": "NEXAVAAR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 767,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 854,
    "pharma_type_other": "SORAFENIB",
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "06d86d68-0fd5-4c6e-8783-ed732a3291e8",
    "patient_ID": "TCGA.CJ.4869",
    "bcr_drug_barcode": "TCGA-CJ-4869-D7279",
    "bcr_drug_uuid": "8941a2e3-132e-40a4-85f2-416e15dd6e44",
    "form_completion_date": "2011-2-8",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 881,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1963,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "dbe16232-525e-4101-9a39-9d4323b10ee9",
    "patient_ID": "TCGA.CJ.4871",
    "bcr_drug_barcode": "TCGA-CJ-4871-D6855",
    "bcr_drug_uuid": "81044ef3-a822-4e52-a82a-895cacf8a4d7",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "ALPHA INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 98,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 65,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "818022ea-123e-438d-9671-542f479028f2",
    "patient_ID": "TCGA.CJ.4875",
    "bcr_drug_barcode": "TCGA-CJ-4875-D6857",
    "bcr_drug_uuid": "3575a7d6-f94c-42a0-8cc3-1ab64eaee621",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "NEXAVAR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1083,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 36,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "24c1cf70-bd67-431e-a623-d20f8d3f52b2",
    "patient_ID": "TCGA.CJ.4881",
    "bcr_drug_barcode": "TCGA-CJ-4881-D6858",
    "bcr_drug_uuid": "78b17dac-e678-491b-97fa-ab8b7c3bcd57",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "TEMSIROLIMUS",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1931,
    "pharmaceutical_tx_ongoing_indicator": true,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "c4bbbcd2-aa18-4b1f-99d4-93279e31d7e7",
    "patient_ID": "TCGA.CJ.4887",
    "bcr_drug_barcode": "TCGA-CJ-4887-D6859",
    "bcr_drug_uuid": "9a7f9dd4-d130-46e4-9171-0a24cb30b914",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 124,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER"
  },
  {
    "bcr_patient_uuid": "f2fca062-ca87-4089-916d-49b9ff146797",
    "patient_ID": "TCGA.CJ.4888",
    "bcr_drug_barcode": "TCGA-CJ-4888-D6860",
    "bcr_drug_uuid": "f7000bb0-6264-451a-bdf1-3561c7f81464",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 576,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1456,
    "drug_cycles": 36,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "46d34d0c-b8a2-4ebd-b9a0-5485904ecafa",
    "patient_ID": "TCGA.CJ.4890",
    "bcr_drug_barcode": "TCGA-CJ-4890-D6861",
    "bcr_drug_uuid": "388898f3-bb79-4469-aaa0-39327882283c",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 211,
    "drug_cycles": 4,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "46d34d0c-b8a2-4ebd-b9a0-5485904ecafa",
    "patient_ID": "TCGA.CJ.4890",
    "bcr_drug_barcode": "TCGA-CJ-4890-D9952",
    "bcr_drug_uuid": "5442b568-0b8a-4115-8b6d-977e5df77929",
    "form_completion_date": "2011-4-4",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 263,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 444,
    "drug_cycles": 6,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "46d34d0c-b8a2-4ebd-b9a0-5485904ecafa",
    "patient_ID": "TCGA.CJ.4890",
    "bcr_drug_barcode": "TCGA-CJ-4890-D9953",
    "bcr_drug_uuid": "0978afe3-0801-4e3a-a499-1f9b4aa63be9",
    "form_completion_date": "2011-4-4",
    "pharmaceutical_therapy_drug_name": "TIPIFARNIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 263,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 444,
    "drug_cycles": 6,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "46d34d0c-b8a2-4ebd-b9a0-5485904ecafa",
    "patient_ID": "TCGA.CJ.4890",
    "bcr_drug_barcode": "TCGA-CJ-4890-D9959",
    "bcr_drug_uuid": "e38d0bef-e746-47e6-a0bc-762fdc1919be",
    "form_completion_date": "2011-4-4",
    "pharmaceutical_therapy_drug_name": "NEXAVAR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1483,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1636,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "46d34d0c-b8a2-4ebd-b9a0-5485904ecafa",
    "patient_ID": "TCGA.CJ.4890",
    "bcr_drug_barcode": "TCGA-CJ-4890-D9961",
    "bcr_drug_uuid": "e1b40910-8c57-4eda-86a4-5f9508be8fba",
    "form_completion_date": "2011-4-4",
    "pharmaceutical_therapy_drug_name": "AFINITOR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1636,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1698,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "46d34d0c-b8a2-4ebd-b9a0-5485904ecafa",
    "patient_ID": "TCGA.CJ.4890",
    "bcr_drug_barcode": "TCGA-CJ-4890-D9956",
    "bcr_drug_uuid": "5916d249-20d8-420a-bd3f-ee16a03ca70d",
    "form_completion_date": "2011-4-4",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 480,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1483,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "d1e4f4c0-08cc-4012-9372-9ab987d80dab",
    "patient_ID": "TCGA.CJ.4894",
    "bcr_drug_barcode": "TCGA-CJ-4894-D6863",
    "bcr_drug_uuid": "a73eac24-7748-4b45-adba-a6bcf5bdce9c",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 188,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 240,
    "drug_cycles": 3,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "b7994839-77a5-4725-aa58-a9e8c79dbfc2",
    "patient_ID": "TCGA.CJ.4895",
    "bcr_drug_barcode": "TCGA-CJ-4895-D6867",
    "bcr_drug_uuid": "9254b0a1-4315-4018-9448-1f18c5680998",
    "form_completion_date": "2011-1-28",
    "pharmaceutical_therapy_drug_name": "TARCEVA",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 45,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "b7994839-77a5-4725-aa58-a9e8c79dbfc2",
    "patient_ID": "TCGA.CJ.4895",
    "bcr_drug_barcode": "TCGA-CJ-4895-D9288",
    "bcr_drug_uuid": "7c8e6a67-e0f7-400b-9bd9-9acda09df66c",
    "form_completion_date": "2011-3-17",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 255,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 740,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "b7994839-77a5-4725-aa58-a9e8c79dbfc2",
    "patient_ID": "TCGA.CJ.4895",
    "bcr_drug_barcode": "TCGA-CJ-4895-D9290",
    "bcr_drug_uuid": "b59b9c89-24a8-40fc-b23f-e050c4132812",
    "form_completion_date": "2011-3-17",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 255,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 740,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "b7994839-77a5-4725-aa58-a9e8c79dbfc2",
    "patient_ID": "TCGA.CJ.4895",
    "bcr_drug_barcode": "TCGA-CJ-4895-D9286",
    "bcr_drug_uuid": "075290aa-7d9e-4f3b-97ee-e3d43f71dc67",
    "form_completion_date": "2011-3-17",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 45,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "33cd8b05-2b9b-40dd-97a2-40d02e27ee90",
    "patient_ID": "TCGA.CJ.4900",
    "bcr_drug_barcode": "TCGA-CJ-4900-D6866",
    "bcr_drug_uuid": "4b92ab24-0a69-42aa-8f86-5ed57a8df17e",
    "form_completion_date": "2011-1-29",
    "pharmaceutical_therapy_drug_name": "TARCEVA",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": -92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 0,
    "drug_cycles": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEO-ADJUVANT"
  },
  {
    "bcr_patient_uuid": "33cd8b05-2b9b-40dd-97a2-40d02e27ee90",
    "patient_ID": "TCGA.CJ.4900",
    "bcr_drug_barcode": "TCGA-CJ-4900-D9257",
    "bcr_drug_uuid": "ed2146fb-1aab-4d45-bad3-c656a4aa11b0",
    "form_completion_date": "2011-3-16",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": -92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 0,
    "drug_cycles": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEO-ADJUVANT"
  },
  {
    "bcr_patient_uuid": "ec3b2a30-fcf6-45ef-bd9d-e6089a237c0f",
    "patient_ID": "TCGA.CJ.4904",
    "bcr_drug_barcode": "TCGA-CJ-4904-D7281",
    "bcr_drug_uuid": "82b2af25-4930-4748-b53a-cd1ab7fd3097",
    "form_completion_date": "2011-2-8",
    "pharmaceutical_therapy_drug_name": "NEXAVAR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 295,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 463,
    "drug_cycles": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "f48fc7d5-ca35-4fdf-8150-0ce34f0f6b3e",
    "patient_ID": "TCGA.CJ.4913",
    "bcr_drug_barcode": "TCGA-CJ-4913-D7284",
    "bcr_drug_uuid": "c1a1fbd4-8cac-48d7-a3d4-ffe8223e52b9",
    "form_completion_date": "2011-2-8",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 861,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1020,
    "drug_cycles": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "267ff78b-bceb-466e-8582-c560fe227ff0",
    "patient_ID": "TCGA.CJ.4918",
    "bcr_drug_barcode": "TCGA-CJ-4918-D7290",
    "bcr_drug_uuid": "7cb2bbac-c189-47ae-a6ce-0812f685b88b",
    "form_completion_date": "2011-2-8",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 36,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 45,
    "drug_cycles": 1,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "25131445-d3cf-46af-b3c5-ca1d1e3561bb",
    "patient_ID": "TCGA.CJ.4923",
    "bcr_drug_barcode": "TCGA-CJ-4923-D7292",
    "bcr_drug_uuid": "1b952d0c-b125-40d0-a5ff-1193c55e8313",
    "form_completion_date": "2011-2-8",
    "pharmaceutical_therapy_drug_name": "PROLEUKIN (IL-2)",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 192,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 379,
    "drug_cycles": 6,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "310c31bf-91ce-40b4-99e4-a10242296de9",
    "patient_ID": "TCGA.CJ.5676",
    "bcr_drug_barcode": "TCGA-CJ-5676-D10768",
    "bcr_drug_uuid": "42bca1a1-845d-44ba-85e9-b6cb7e3fffad",
    "form_completion_date": "2011-4-26",
    "pharmaceutical_therapy_drug_name": "ONCOPHAGE VACCINE",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 69,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 209,
    "drug_cycles": 13,
    "pharma_type_other": "VACCINE",
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "310c31bf-91ce-40b4-99e4-a10242296de9",
    "patient_ID": "TCGA.CJ.5676",
    "bcr_drug_barcode": "TCGA-CJ-5676-D10782",
    "bcr_drug_uuid": "7a7b6d14-0d90-436b-9fe0-d65d3bf9a162",
    "form_completion_date": "2011-4-26",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2227,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG/KG/DAY",
    "drug_dose": 800,
    "regimen_number": 2,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "d2664fde-ce3b-45e6-9a23-4a07980f7bac",
    "patient_ID": "TCGA.CJ.5677",
    "bcr_drug_barcode": "TCGA-CJ-5677-D10784",
    "bcr_drug_uuid": "fba74882-fb5f-43f2-8edd-945f9ed59003",
    "form_completion_date": "2011-4-26",
    "pharmaceutical_therapy_drug_name": "INTERFERON-ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 70,
    "drug_cycles": 2,
    "drug_dose": 2,
    "regimen_number": 2,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "d2664fde-ce3b-45e6-9a23-4a07980f7bac",
    "patient_ID": "TCGA.CJ.5677",
    "bcr_drug_barcode": "TCGA-CJ-5677-D10783",
    "bcr_drug_uuid": "96ff23fe-4534-42bf-af6f-e7d81301737f",
    "form_completion_date": "2011-4-26",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 70,
    "drug_cycles": 2,
    "drug_units": "G/M2",
    "drug_tota_dose_units": "G/DAY",
    "drug_dose": 1,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 2
  },
  {
    "bcr_patient_uuid": "d2664fde-ce3b-45e6-9a23-4a07980f7bac",
    "patient_ID": "TCGA.CJ.5677",
    "bcr_drug_barcode": "TCGA-CJ-5677-D10785",
    "bcr_drug_uuid": "795bcad0-cfa4-4568-9726-bba045ea3853",
    "form_completion_date": "2011-4-26",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 378,
    "drug_cycles": 5,
    "drug_units": "MG/M2",
    "drug_dose": 600,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "822cf6c1-dd65-4814-94b1-0c335208ad9b",
    "patient_ID": "TCGA.CJ.5678",
    "bcr_drug_barcode": "TCGA-CJ-5678-D10850",
    "bcr_drug_uuid": "e9fb1132-a565-44ed-a4d2-4117f1666ee4",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "ONCOPHAGE VACCINE",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 43,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 93,
    "drug_cycles": 6,
    "drug_units": "ML",
    "drug_dose": 0.2,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "3fa6c93e-e7fe-402c-9526-c81411aa0920",
    "patient_ID": "TCGA.CJ.5679",
    "bcr_drug_barcode": "TCGA-CJ-5679-D10851",
    "bcr_drug_uuid": "02a170ea-b4b2-42e7-840f-cc589ab99671",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "INTERFERON-ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 116,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 274,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3fa6c93e-e7fe-402c-9526-c81411aa0920",
    "patient_ID": "TCGA.CJ.5679",
    "bcr_drug_barcode": "TCGA-CJ-5679-D10856",
    "bcr_drug_uuid": "ea807644-32c7-48bd-b2e8-1cbd56f6b3cf",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "THALIDOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 547,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 599,
    "drug_units": "MG/DAY",
    "drug_dose": 100,
    "regimen_number": 5,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3fa6c93e-e7fe-402c-9526-c81411aa0920",
    "patient_ID": "TCGA.CJ.5679",
    "bcr_drug_barcode": "TCGA-CJ-5679-D10855",
    "bcr_drug_uuid": "ffd8b92a-6b6b-4cca-bf82-9e943e3237d9",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 344,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 547,
    "drug_cycles": 16,
    "drug_units": "MG/KG",
    "drug_dose": 10,
    "regimen_number": 4,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "3fa6c93e-e7fe-402c-9526-c81411aa0920",
    "patient_ID": "TCGA.CJ.5679",
    "bcr_drug_barcode": "TCGA-CJ-5679-D10852",
    "bcr_drug_uuid": "af2a8ba4-39b6-4e03-ac73-85be416132d1",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 274,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 344,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG/WK",
    "drug_dose": 1000,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 1970
  },
  {
    "bcr_patient_uuid": "3fa6c93e-e7fe-402c-9526-c81411aa0920",
    "patient_ID": "TCGA.CJ.5679",
    "bcr_drug_barcode": "TCGA-CJ-5679-D10853",
    "bcr_drug_uuid": "f4bd6ee0-f8e7-4eba-9a5b-164cd3208007",
    "form_completion_date": "2011-4-29",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 274,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 344,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "5db69ebe-38db-4ef3-b825-674b4a6ddaee",
    "patient_ID": "TCGA.CJ.5680",
    "bcr_drug_barcode": "TCGA-CJ-5680-D10871",
    "bcr_drug_uuid": "67fa6309-b5ad-4f62-a60e-adc3304e2632",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "IL-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 220,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 247,
    "drug_cycles": 15,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "5db69ebe-38db-4ef3-b825-674b4a6ddaee",
    "patient_ID": "TCGA.CJ.5680",
    "bcr_drug_barcode": "TCGA-CJ-5680-D10874",
    "bcr_drug_uuid": "604063dd-ab5f-4ad4-aa71-072f8af66077",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 275,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 616,
    "drug_cycles": 24,
    "drug_units": "MG/KG",
    "drug_dose": 10,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "5db69ebe-38db-4ef3-b825-674b4a6ddaee",
    "patient_ID": "TCGA.CJ.5680",
    "bcr_drug_barcode": "TCGA-CJ-5680-D10857",
    "bcr_drug_uuid": "852a6313-ee15-421c-9683-e3b07d970f1d",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "ONCOPHAGE VACCINE",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 186,
    "drug_cycles": 12,
    "drug_units": "ML",
    "drug_tota_dose_units": "ML",
    "drug_dose": 0.2,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 2.4
  },
  {
    "bcr_patient_uuid": "5db69ebe-38db-4ef3-b825-674b4a6ddaee",
    "patient_ID": "TCGA.CJ.5680",
    "bcr_drug_barcode": "TCGA-CJ-5680-D12649",
    "bcr_drug_uuid": "a694a74a-e10e-4276-96b5-4d17abfb4681",
    "form_completion_date": "2011-6-5",
    "pharmaceutical_therapy_drug_name": "TARCEVA",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 466,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 629,
    "drug_cycles": 1,
    "drug_units": "MG/DAY",
    "drug_dose": 150,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2939c03a-6f3f-4f7b-b246-34361baadeb9",
    "patient_ID": "TCGA.CJ.5681",
    "bcr_drug_barcode": "TCGA-CJ-5681-D10876",
    "bcr_drug_uuid": "fd23322f-f22f-47b9-b46b-55f1031aa4a9",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 165,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 235,
    "drug_cycles": 3,
    "drug_units": "MG/KG",
    "drug_dose": 10,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2939c03a-6f3f-4f7b-b246-34361baadeb9",
    "patient_ID": "TCGA.CJ.5681",
    "bcr_drug_barcode": "TCGA-CJ-5681-D10875",
    "bcr_drug_uuid": "b54c8012-1258-4b9b-8bbb-3899e82aa8e8",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "IL-2",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 135,
    "drug_cycles": 2,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2939c03a-6f3f-4f7b-b246-34361baadeb9",
    "patient_ID": "TCGA.CJ.5681",
    "bcr_drug_barcode": "TCGA-CJ-5681-D10877",
    "bcr_drug_uuid": "d870b922-3cc1-4273-8cb7-aef6b75eaa13",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 235,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 318,
    "drug_cycles": 4,
    "drug_units": "MG/KG",
    "drug_dose": 650,
    "regimen_number": 3,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2939c03a-6f3f-4f7b-b246-34361baadeb9",
    "patient_ID": "TCGA.CJ.5681",
    "bcr_drug_barcode": "TCGA-CJ-5681-D10878",
    "bcr_drug_uuid": "24d2fd79-c834-49b6-bb48-616a5f935835",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "RAD001",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 305,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 365,
    "regimen_number": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "4c325ee1-9b8e-45d4-a0a7-e47ec1eac402",
    "patient_ID": "TCGA.CJ.5682",
    "bcr_drug_barcode": "TCGA-CJ-5682-D10879",
    "bcr_drug_uuid": "6ac833df-b07a-4a38-8395-f41b36572b14",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "INTERFERON ALPHA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 813,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2890b330-8ba5-4031-bed5-13e9d1d75af9",
    "patient_ID": "TCGA.CJ.6028",
    "bcr_drug_barcode": "TCGA-CJ-6028-D14112",
    "bcr_drug_uuid": "efec152d-14e5-41dc-93aa-d91112f20a91",
    "form_completion_date": "2011-7-21",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 392,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 903,
    "drug_cycles": 2,
    "drug_units": "MG/M2",
    "drug_dose": 600,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2890b330-8ba5-4031-bed5-13e9d1d75af9",
    "patient_ID": "TCGA.CJ.6028",
    "bcr_drug_barcode": "TCGA-CJ-6028-D14113",
    "bcr_drug_uuid": "575516b7-e4d4-44f7-ba47-2853ce7409ee",
    "form_completion_date": "2011-7-21",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 392,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 903,
    "drug_cycles": 2,
    "drug_units": "MG/M2/DAY",
    "drug_dose": 1500,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2890b330-8ba5-4031-bed5-13e9d1d75af9",
    "patient_ID": "TCGA.CJ.6028",
    "bcr_drug_barcode": "TCGA-CJ-6028-D14115",
    "bcr_drug_uuid": "8cc18e98-54bc-4edb-aed9-fa4d69f9c5bb",
    "form_completion_date": "2011-7-21",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1033,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1625,
    "drug_units": "MG/DAY",
    "drug_dose": 400,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "2890b330-8ba5-4031-bed5-13e9d1d75af9",
    "patient_ID": "TCGA.CJ.6028",
    "bcr_drug_barcode": "TCGA-CJ-6028-D14100",
    "bcr_drug_uuid": "a4e4b7e8-5549-4cbe-a05b-ddccae7c87e3",
    "form_completion_date": "2011-7-21",
    "pharmaceutical_therapy_drug_name": "ONCOPHAGE",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 130,
    "pharma_type_other": "VACCINE",
    "drug_units": "ML",
    "drug_tota_dose_units": "ML",
    "drug_dose": 0.4,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "TREATMENT OF METASTATIC DISEASE FOLLOWING CYTOREDUCTIVE NEPHRECTOMY",
    "drug_total_dose": 3.6
  },
  {
    "bcr_patient_uuid": "2890b330-8ba5-4031-bed5-13e9d1d75af9",
    "patient_ID": "TCGA.CJ.6028",
    "bcr_drug_barcode": "TCGA-CJ-6028-D14114",
    "bcr_drug_uuid": "9f0055bf-dd02-48b4-a681-cfa9fd95322c",
    "form_completion_date": "2011-7-21",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 903,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1033,
    "drug_tota_dose_units": "MG/DAY",
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 50
  },
  {
    "bcr_patient_uuid": "2890b330-8ba5-4031-bed5-13e9d1d75af9",
    "patient_ID": "TCGA.CJ.6028",
    "bcr_drug_barcode": "TCGA-CJ-6028-D14102",
    "bcr_drug_uuid": "d0ce80e2-94c1-40bd-90aa-386450af25c2",
    "form_completion_date": "2011-7-21",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 336,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 392,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "4edff57f-4b0e-4770-beac-590da7d7232c",
    "patient_ID": "TCGA.CJ.6033",
    "bcr_drug_barcode": "TCGA-CJ-6033-D16327",
    "bcr_drug_uuid": "6c623ee3-2d55-46d5-ae7d-9347dd0a4752",
    "form_completion_date": "2011-8-16",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 32,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 74,
    "drug_cycles": 2,
    "drug_units": "MG/DAY",
    "drug_dose": 2500,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "TREATMENT OF METASTATIC DISEASE FOLLOWING CYTOREDUCTIVE NEPHRECTOMY"
  },
  {
    "bcr_patient_uuid": "4edff57f-4b0e-4770-beac-590da7d7232c",
    "patient_ID": "TCGA.CJ.6033",
    "bcr_drug_barcode": "TCGA-CJ-6033-D16330",
    "bcr_drug_uuid": "1a8e76f1-de11-4c9b-96d3-71a05c0e2f39",
    "form_completion_date": "2011-9-16",
    "pharmaceutical_therapy_drug_name": "INTERFERON",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 144,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 172,
    "drug_dose": 500000,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "4edff57f-4b0e-4770-beac-590da7d7232c",
    "patient_ID": "TCGA.CJ.6033",
    "bcr_drug_barcode": "TCGA-CJ-6033-D16329",
    "bcr_drug_uuid": "71a0a459-12f4-4fca-bb66-42ce0f871f34",
    "form_completion_date": "2011-9-16",
    "pharmaceutical_therapy_drug_name": "IRESSA",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 74,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 144,
    "drug_units": "MG/DAY",
    "drug_dose": 250,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METISTATIC DISEASE"
  },
  {
    "bcr_patient_uuid": "4edff57f-4b0e-4770-beac-590da7d7232c",
    "patient_ID": "TCGA.CJ.6033",
    "bcr_drug_barcode": "TCGA-CJ-6033-D16328",
    "bcr_drug_uuid": "4f5e45e8-f08e-4def-a405-7c6128d41653",
    "form_completion_date": "2011-9-16",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 81,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 144,
    "drug_units": "MG/KG",
    "drug_dose": 10,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "METISTATIC DISEASE"
  },
  {
    "bcr_patient_uuid": "4edff57f-4b0e-4770-beac-590da7d7232c",
    "patient_ID": "TCGA.CJ.6033",
    "bcr_drug_barcode": "TCGA-CJ-6033-D16326",
    "bcr_drug_uuid": "361f2192-be38-459e-919f-e7fcd6f19a6b",
    "form_completion_date": "2011-9-16",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 32,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 74,
    "drug_cycles": 2,
    "drug_units": "MG/M2/DAY",
    "drug_dose": 600,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "TREATMENT OF METASTATIC DISEASE FOLLOWING CYTOREDUCTIVE NEPHRECTOMY"
  },
  {
    "bcr_patient_uuid": "88fc4bc4-32cf-4d92-8c29-20d920b8f719",
    "patient_ID": "TCGA.CW.5580",
    "bcr_drug_barcode": "TCGA-CW-5580-D8584",
    "bcr_drug_uuid": "b1ebaccd-72cc-42a8-9286-50085222d185",
    "form_completion_date": "2011-3-1",
    "pharmaceutical_therapy_drug_name": "IFN-ALPHA (INTRON)",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 57
  },
  {
    "bcr_patient_uuid": "0487fc41-386c-4d76-9084-daf959bf5e98",
    "patient_ID": "TCGA.CW.5585",
    "bcr_drug_barcode": "TCGA-CW-5585-D8594",
    "bcr_drug_uuid": "9adc6edd-2e8a-41ce-a364-51a4b140feaa",
    "form_completion_date": "2011-3-1",
    "pharmaceutical_therapy_drug_name": "SUTENT (SUNITINIB)",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 2563
  },
  {
    "bcr_patient_uuid": "9fd9104b-a26d-44c7-bb45-f1edd76d0aa0",
    "patient_ID": "TCGA.CW.5590",
    "bcr_drug_barcode": "TCGA-CW-5590-D8614",
    "bcr_drug_uuid": "1ca0a85b-5ae1-4a31-b005-c1fcf6d6520c",
    "form_completion_date": "2011-3-1",
    "pharmaceutical_therapy_drug_name": "SUTENT (SUNITINIB)",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 229,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 956,
    "pharma_type_other": "SU011248"
  },
  {
    "bcr_patient_uuid": "f1ae0181-74f8-47fd-83be-83a7d01101cc",
    "patient_ID": "TCGA.CW.5591",
    "bcr_drug_barcode": "TCGA-CW-5591-D8621",
    "bcr_drug_uuid": "ecc5564d-d0e9-4b6a-9377-90a001040e2c",
    "form_completion_date": "2011-3-1",
    "pharmaceutical_therapy_drug_name": "IL-2 (HIGH DOSE)",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 78
  },
  {
    "bcr_patient_uuid": "5f53ace3-14ca-412a-af6c-98d8996f8177",
    "patient_ID": "TCGA.CW.6097",
    "bcr_drug_barcode": "TCGA-CW-6097-D12249",
    "bcr_drug_uuid": "f98c52fa-e5ad-4e18-ba98-dd31d1b92347",
    "form_completion_date": "2011-5-26",
    "pharmaceutical_therapy_drug_name": "BAY-439006",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 115,
    "pharmaceutical_tx_ongoing_indicator": false,
    "pharma_type_other": "CLINICAL TRIAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "d5213422-9447-4f62-b486-3303e3f991fa",
    "patient_ID": "TCGA.CZ.4857",
    "bcr_drug_barcode": "TCGA-CZ-4857-D7709",
    "bcr_drug_uuid": "95cecfe0-ba80-4008-866f-7174a86b8bf5",
    "form_completion_date": "2011-2-14",
    "pharmaceutical_therapy_drug_name": "IL-2 THERAPY (INTERLEUKIN)",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 228,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 247,
    "drug_cycles": 1,
    "pharma_type_other": "BIOLOGICAL THERAPY",
    "drug_units": "[IU]/KG",
    "drug_tota_dose_units": "[IU]/KG",
    "drug_route": "INTRAVENOUS",
    "drug_total_dose": 1177
  },
  {
    "bcr_patient_uuid": "f06bdea2-4528-4a14-9cea-280af6b4c702",
    "patient_ID": "TCGA.CZ.4858",
    "bcr_drug_barcode": "TCGA-CZ-4858-D7716",
    "bcr_drug_uuid": "6e51f78f-a493-4217-a249-35ddd5602891",
    "form_completion_date": "2011-2-14",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN 2-HIGH DOSE",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 1694,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1715,
    "drug_cycles": 2,
    "pharma_type_other": "BIOLOGICAL THERAPY",
    "drug_units": "[IU]/KG",
    "drug_tota_dose_units": "[IU]/KG",
    "drug_dose": 600,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 1360
  },
  {
    "bcr_patient_uuid": "6949efc1-4f71-4141-b129-a54b4bde5d2f",
    "patient_ID": "TCGA.CZ.4860",
    "bcr_drug_barcode": "TCGA-CZ-4860-D7726",
    "bcr_drug_uuid": "b9f157fa-713b-4fb9-b671-f5f15b0f1bac",
    "form_completion_date": "2011-2-14",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 53,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 132,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "226ce515-c12c-4195-bb5d-d6df2e135ff6",
    "patient_ID": "TCGA.CZ.4861",
    "bcr_drug_barcode": "TCGA-CZ-4861-D20605",
    "bcr_drug_uuid": "689f0d94-bd0a-4fc4-a67a-046aa3514ef9",
    "form_completion_date": "2012-1-18",
    "pharmaceutical_therapy_drug_name": "SORAFENIB - NEXAVAR",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": -43,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 32,
    "drug_cycles": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "OTHER",
    "therapy_regimen_other": "NEOADJUVANT"
  },
  {
    "bcr_patient_uuid": "f2801b21-5444-4cc3-a642-c60c6d82cd3d",
    "patient_ID": "TCGA.CZ.5454",
    "bcr_drug_barcode": "TCGA-CZ-5454-D8994",
    "bcr_drug_uuid": "e9789b15-22f2-4464-98f1-4cf7ecbe2e15",
    "form_completion_date": "2011-3-10",
    "pharmaceutical_therapy_drug_name": "SUTENT (SUNITINIB)",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 37,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 324,
    "drug_cycles": 7,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 37.5,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 8925
  },
  {
    "bcr_patient_uuid": "467bf226-a646-4217-bce6-8d0f11c756eb",
    "patient_ID": "TCGA.CZ.5456",
    "bcr_drug_barcode": "TCGA-CZ-5456-D9019",
    "bcr_drug_uuid": "164714d6-5bec-464c-885c-4d81682616cd",
    "form_completion_date": "2011-3-11",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1124,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1286,
    "drug_cycles": 4,
    "drug_units": "MG",
    "drug_dose": 800,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "a7ddd737-714d-423f-8fb5-5a932d014487",
    "patient_ID": "TCGA.CZ.5460",
    "bcr_drug_barcode": "TCGA-CZ-5460-D9029",
    "bcr_drug_uuid": "f2fe44fb-e4b3-4b41-8fbd-6c99c5b15dfa",
    "form_completion_date": "2011-3-11",
    "pharmaceutical_therapy_drug_name": "INTERLEUKIN-2",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 174,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 298,
    "drug_cycles": 2,
    "pharma_type_other": "BIOLOGICAL THERAPY",
    "drug_units": "[IU]/KG",
    "drug_tota_dose_units": "[IU]/KG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 2138
  },
  {
    "bcr_patient_uuid": "393abcf7-1155-4b32-85ca-cd44d259e4b4",
    "patient_ID": "TCGA.CZ.5461",
    "bcr_drug_barcode": "TCGA-CZ-5461-D9042",
    "bcr_drug_uuid": "ad2f500b-aa23-44fe-86c6-2c45706d2065",
    "form_completion_date": "2011-3-11",
    "pharmaceutical_therapy_drug_name": "SUNITINIB (SUTENT)",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 45,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 278,
    "drug_cycles": 5,
    "drug_units": "MG/DAY",
    "drug_tota_dose_units": "MG",
    "drug_dose": 50,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 7000
  },
  {
    "bcr_patient_uuid": "e0127e51-43ba-4536-bc9d-004591f9c627",
    "patient_ID": "TCGA.CZ.5462",
    "bcr_drug_barcode": "TCGA-CZ-5462-D9045",
    "bcr_drug_uuid": "71a635c2-508f-4151-b41c-0542821055e0",
    "form_completion_date": "2011-3-11",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 15,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 127,
    "drug_units": "MG/DAY",
    "drug_dose": 50,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "6b79d20c-d5bc-4580-837e-b36dfd0c199c",
    "patient_ID": "TCGA.CZ.5464",
    "bcr_drug_barcode": "TCGA-CZ-5464-D9059",
    "bcr_drug_uuid": "a7793c40-e76c-4b4e-92da-e30f7a1c58b2",
    "form_completion_date": "2011-3-11",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 571,
    "drug_units": "MG/DAY",
    "drug_dose": 50,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "6b79d20c-d5bc-4580-837e-b36dfd0c199c",
    "patient_ID": "TCGA.CZ.5464",
    "bcr_drug_barcode": "TCGA-CZ-5464-D19220",
    "bcr_drug_uuid": "27449df9-bfc7-40cf-a102-4e3024f8b6b0",
    "form_completion_date": "2011-12-6",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1407,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1730,
    "drug_units": "MG",
    "drug_dose": 800,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "6205c2d8-d431-4c4c-8ac6-ee407170e833",
    "patient_ID": "TCGA.CZ.5469",
    "bcr_drug_barcode": "TCGA-CZ-5469-D9073",
    "bcr_drug_uuid": "51e67e71-cb66-4363-b6fb-7c6cb7037aed",
    "form_completion_date": "2011-3-11",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 223,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 597,
    "drug_units": "MG/DAY",
    "drug_dose": 37.5,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "f6d28a1d-6691-4ac1-8afb-ab0e7dcef867",
    "patient_ID": "TCGA.DV.5565",
    "bcr_drug_barcode": "TCGA-DV-5565-D13877",
    "bcr_drug_uuid": "aff45daf-b926-4e59-80ac-70ba3f35d908",
    "form_completion_date": "2011-7-18",
    "pharmaceutical_therapy_drug_name": "ZD6474",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1189,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_dose": 200,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE"
  },
  {
    "bcr_patient_uuid": "EF2D7EF5-CDFC-48C9-B3FE-6EAF3BE1106D",
    "patient_ID": "TCGA.DV.A4VX",
    "bcr_drug_barcode": "TCGA-DV-A4VX-D39044",
    "bcr_drug_uuid": "7880BC8A-7E1D-42DB-A721-6B336D67A093",
    "form_completion_date": "2013-12-3",
    "pharmaceutical_therapy_drug_name": "SUNITINIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 56,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 482,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "EF2D7EF5-CDFC-48C9-B3FE-6EAF3BE1106D",
    "patient_ID": "TCGA.DV.A4VX",
    "bcr_drug_barcode": "TCGA-DV-A4VX-D39045",
    "bcr_drug_uuid": "0E637E76-7F7E-442D-B3DE-F1737B52A179",
    "form_completion_date": "2013-12-3",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 482,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1503,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "3F0A2571-C088-4735-8152-61F6FD60AC63",
    "patient_ID": "TCGA.G6.A5PC",
    "bcr_drug_barcode": "TCGA-G6-A5PC-D44703",
    "bcr_drug_uuid": "5DC3019B-3C23-44EF-9AE9-FF381CF2320F",
    "form_completion_date": "2013-6-25",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 208,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "28011111-4A01-4CDC-8D6B-7223FB2C501B",
    "patient_ID": "TCGA.G6.A8L6",
    "bcr_drug_barcode": "TCGA-G6-A8L6-D58227",
    "bcr_drug_uuid": "8CA2D5C3-74D7-46B8-BA9B-52BEB3D62017",
    "form_completion_date": "2014-4-2",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 276,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "28011111-4A01-4CDC-8D6B-7223FB2C501B",
    "patient_ID": "TCGA.G6.A8L6",
    "bcr_drug_barcode": "TCGA-G6-A8L6-D58225",
    "bcr_drug_uuid": "2D08B0B9-FCAE-43BE-92B4-1D58B09E5E00",
    "form_completion_date": "2014-4-3",
    "pharmaceutical_therapy_drug_name": "SUTENT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 73,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 211,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "28011111-4A01-4CDC-8D6B-7223FB2C501B",
    "patient_ID": "TCGA.G6.A8L6",
    "bcr_drug_barcode": "TCGA-G6-A8L6-D58226",
    "bcr_drug_uuid": "55CA8E78-C80B-4957-8A71-16D55025F6D7",
    "form_completion_date": "2014-4-3",
    "pharmaceutical_therapy_drug_name": "AXITNIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 252,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 272,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  }
]
